Hémochromatoses et autres surcharges hépatiques en fer

Deugnier, Yves; Lainé, Fabrice; Lan, Caroline Le; Bardou-Jacquet, Édouard; Jouanolle, Anne–Marie; Brissot, Pierre

doi:10.1016/s1155-1976(11)40364-8

Cited by 3 publications

(2 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondary hemosiderosis has become a frequent phenomenon in dialysis 4,5 . Iron overload leads to excessive iron deposition in various tissues; liver, heart, endocrine, and immune system, 6 with serious consequences for heart, liver (cirrhosis and even a risk of liver cancer) 7,8 . Diagnosis formerly provided by liver biopsy, is now easily made by hepatic MRI (without gadolinium injection), which has become the “gold standard” for the diagnosis and monitoring of martial overload 9,10 .…”

Section: Introductionmentioning

confidence: 99%

“…4,5 Iron overload leads to excessive iron deposition in various tissues; liver, heart, endocrine, and immune system, 6 with serious consequences for heart, liver (cirrhosis and even a risk of liver cancer). 7,8 Diagnosis formerly provided by liver biopsy, is now easily made by hepatic MRI (without gadolinium injection), which has become the "gold standard" for the diagnosis and monitoring of martial overload. 9,10 The serious consequences of this iron overload, especially in this type of population already weakened by numerous co-morbidities, require early management.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hemosiderosis in chronic dialysis patients: Monitoring the response to deferasirox by quantitative hepatic magnetic resonance imaging

Bekhechi

Chiali

Khelil

et al. 2023

Hemodialysis International

View full text Add to dashboard Cite

Introduction: Hemosiderosis of chronic dialysis has always been a frequent phenomenon in dialysis; formerly related to blood transfusions before the advent of Erythropoiesis Stimulating Agents (ESA), it is currently in connection with the use of massive doses of injectable iron, to ensure the full therapeutic efficacy of ESA. Few studies have looked at the therapeutic aspect of iron chelators in the dialysis population.Methods: We followed 31 dialysis patients treated for secondary hemosiderosis with deferasirox (DFX) at the dose 10 mg/kg/day, by hepatic MRI from September 2017 to September 2021, in order to evaluate the efficacy of iron chelators on the reduction of liver iron concentration (LIC). The diagnosis of hemosiderosis was carried for a value of the LIC > 50 μmol/g of dry liver.Results: Chelation resulted in a significant reduction in liver iron burden as measured by liver MRI: (201.4 ± 179.9 vs. 122.6 ± 154.3 μmol/g liver)

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Hemosiderosis in chronic dialysis patients: Monitoring the response to deferasirox by quantitative hepatic magnetic resonance imaging

Bekhechi

Chiali

Khelil

et al. 2023

Hemodialysis International

View full text Add to dashboard Cite

show abstract

Hémochromatose héréditaire : circonstances de découverte et délais diagnostiques

Gasser

Courtois²,

Hojjat-Assari

et al. 2014

La Revue de Médecine Interne

View full text Add to dashboard Cite

Compound Heterozygous C282Y/H63D Mutation in Hemochromatosis: A Case Report

Zazour¹,

Khannoussi²,

Mekkaoui³

et al. 2016

OJCD

View full text Add to dashboard Cite

Hereditary hemochromatosis is a condition characterized by iron overload, which is both treatable and preventable. It's mainly related to hepcidin deficiency related to mutations in genes involved in hepcidin regulation. Iron overload increases the risk of disease such as liver cirrhosis, heart disease and diabetes. Two HFE genotypes have been commonly described in cases of iron overload, C282Y homozygosity and C282Y/H63D compound heterozygoty. The diagnosis of this rare disease now can be explored by biological and imaging tools. We report a case of compound heterozygous C282Y/H63D discovered by family screening for elevated serum ferritin.

show abstract

Hémochromatoses et autres surcharges hépatiques en fer

Cited by 3 publications

References 98 publications

Hemosiderosis in chronic dialysis patients: Monitoring the response to deferasirox by quantitative hepatic magnetic resonance imaging

Hemosiderosis in chronic dialysis patients: Monitoring the response to deferasirox by quantitative hepatic magnetic resonance imaging

Hémochromatose héréditaire : circonstances de découverte et délais diagnostiques

Compound Heterozygous C282Y/H63D Mutation in Hemochromatosis: A Case Report

Contact Info

Product

Resources

About